about
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximabImmunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 casesPredictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatmentSurvival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyInterferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infectionResponse to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
P50
Q48370192-7E5DB1B7-7272-48CD-B1CE-5A0E832C8D26Q88195212-C6041563-8584-4AC6-82D1-0FD5DAAB390BQ89469980-E5B4078E-7ECC-41F7-B5B0-17FA8E672BACQ90435853-E749C827-301D-41C1-8196-331C91B2A882Q91893828-EDBA279F-DD7C-4A28-B193-24A6B9D79EC3Q91973993-BF9FC351-4E3E-4725-B001-84B1BDE5B8CEQ96576751-789D00F6-49ED-42DE-ABC2-28DA4C5E59CA
P50
description
researcher
@en
wetenschapper
@nl
name
Massimo Gentile
@en
Massimo Gentile
@nl
type
label
Massimo Gentile
@en
Massimo Gentile
@nl
prefLabel
Massimo Gentile
@en
Massimo Gentile
@nl
P31
P496
0000-0002-5256-0726